HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price

Oculis (NASDAQ:OCS) had its target price hoisted by stock analysts at HC Wainwright from $42.00 to $44.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 57.20% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and issued a $51.00 target price on shares of Oculis in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Needham & Company LLC boosted their price target on Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Bank of America lowered their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Oculis Price Performance

NASDAQ OCS traded up $0.42 on Wednesday, reaching $27.99. 185,343 shares of the company’s stock traded hands, compared to its average volume of 308,178. Oculis has a 12 month low of $14.00 and a 12 month high of $30.68. The stock has a market cap of $1.47 billion, a PE ratio of -11.11 and a beta of 0.29. The stock has a 50-day simple moving average of $25.74 and a 200 day simple moving average of $21.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.14 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, research analysts predict that Oculis will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new position in Oculis in the fourth quarter valued at $9,862,000. Millennium Management LLC purchased a new position in shares of Oculis during the fourth quarter worth about $312,000. NEXTBio Capital Management LP acquired a new position in Oculis in the 4th quarter valued at about $2,991,000. Marshall Wace LLP purchased a new stake in Oculis during the 4th quarter valued at approximately $914,000. Finally, Alyeska Investment Group L.P. lifted its position in Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.